Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a nerve drug help botulism patients breathe easier?

NCT ID NCT01441557

Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This small pilot study tested a drug called 3,4-diaminopyridine (FIRDAPSE) in 3 people with severe botulism who needed a ventilator to breathe. The goal was to see if the drug could improve nerve signals and breathing. Because only 3 people took part, the results are very preliminary and not enough to draw firm conclusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
3,4-diaminopyridine (FIRDAPSE)
What this could lead to
If it works, this drug could help botulism patients breathe better and recover muscle function faster.
What could go wrong
This was a tiny pilot study with only 3 participants, so results may not apply widely. The drug may cause side effects like seizures or heart issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

3 people

The number who actually took part.

Start date

Sep 2011

Finished

Mar 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * botulism * ventilation Exclusion Criteria: * renal failure * cardiac failure * pregnancy * under age 18 * hepatic failure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Botulism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

botulism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Botulism

Contacts and locations

Locations

  • CHU

    Amiens, 80000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.